Copyright: ©Author(s) 2026.
World J Gastroenterol. Jul 14, 2026; 32(26): 118151
Published online Jul 14, 2026. doi: 10.3748/wjg.118151
Published online Jul 14, 2026. doi: 10.3748/wjg.118151
Table 2 Summarized guidelines for colorectal cancer screening from different regions
| Country/association | Target group | Recommendation | Average risk person definition |
| USPTF, 2021[28] | Asymptomatic adults at average risk of colorectal cancer. 50-75 years (A recommendation). 45-49 years (B recommendation) | High-sensitivity G-FOBT or FIT every year. sDNA-FIT every 1 to 3 years. CTC every 5 years. Flexible sigmoidoscopy every 5 years. Flexible sigmoidoscopy every 10 years + FIT every year. Colonoscopy screening every 10 years | No prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer (such as Lynch syndrome or familial adenomatous polyposis) |
| MTSTF, 2022[96] | Average-risk adults aged 45-75 years | High-quality colonoscopy every 10 years or an annual FIT (strong recommendation; moderate-quality evidence). Flexible sigmoidoscopy every 5 years to 10 years (strong recommendation; high-quality evidence). CTC every 5 years (strong recommendation, low-quality evidence). FIT–fecal DNA every 3 years (strong recommendation, low-quality evidence) in individuals who decline colonoscopy and a FIT | Those aged 50-75 years with no history of CRC or adenoma, with no first-degree relatives with CRC, and who are not up to date with CRC screening according to other methods (that is, sigmoidoscopy within 5 years or colonoscopy within 10 years) |
| ACP, 2023[92] | Asymptomatic average-risk adults aged 50-75 years | A FIT or high-sensitivity G-FOBT every 2 years, colonoscopy every 10 years, or flexible sigmoidoscopy every 10 years plus a FIT every 2 years | No prior diagnosis of CRC, adenomatous polyps, or inflammatory bowel disease, and no personal diagnosis or family history of known genetic disorders that predispose a person to a high lifetime risk for CRC (for example, Lynch syndrome) |
| ACS, 2018[11] | Average-risk adults aged 45-75 years | Annual FIT. Annual high-sensitivity G-FOBT. mt-sDNA test every 3 years. Colonoscopy every 10 years. CTC every 5 years. Flexible sigmoidoscopy every 5 years | Persons without a history of adenomatous polyps or CRC and not at increased risk for CRC due to a family history of CRC, a confirmed or suspected hereditary CRC syndrome (such as familial adenomatous polyposis or Lynch syndrome), a personal history of abdominal or pelvic radiation for a previous cancer, or a personal history of inflammatory bowel disease |
| NCCN, 2024[97] | Adults aged 45-70 years | For individuals at average risk, the choice of a particular screening modality should include a conversation with the patient concerning their preference and availability, for individuals at increased risk, colonoscopy is the preferred method | Aged 45-75 years; no personal history of adenoma or SSP/SSL or CRC; no personal history of IBD; no personal history of high-risk CRC genetic syndromes (list of syndromes on CSCR-2); no personal history of cystic fibrosis; no personal history of childhood cancer; negative family history for confirmed advanced adenoma (i.e., high-grade dysplasia, 21 cm, villous tubulovillous histology) or an advanced SP/SSL, (≥ 1 cm, any dysplasia) in first-degree relatives. Negative family history for CRC |
| The Asia-Pacific region, 2022[98] | Adults aged 50-year. Using age alone as a cut-off point for CRC screening is insufficient. Decision should be made by patients and clinicians together based on a patient’s overall health status, prior screening history and patient’s preferences | Quantitative FIT (every year or every 2 years) or colonoscopy (every 10 years) | - |
| The European Colorectal Cancer Screening Guidelines Working Group, 2013[99] | Adults aged 50-74 years residing in the target area | Recommendation based on good evidence for G-FOBT, reasonable evidence for FIT and flexible sigmoidoscopy, and limited evidence for colonoscopy | - |
| National Cancer Center of China, 2020[100] | Low-to-average-risk adults aged 50-75 years (strong recommendation, moderate-quality evidence). High-risk adults aged 40-75 years (strong recommendation, moderate-quality evidence) | - | No first-degree relatives with a CRC diagnosis; no personal diagnosis of adenomatous polyps or CRC; no history of inflammatory bowel over 8-10 years; no positive G-GOBT results |
| The Canadian Association of Gastroenterology, 2018[101] | All individuals with a family history of CRC or documented adenoma. 50-75 years | Colonoscopy is suggested (recommended in individuals with ≥ 2 first-degree relatives), with FIT as an alternative | - |
| The Saudi Arabian Ministry of Health, 2015[102] | Average-risk adults aged 45-70 years | Colonoscopy alone every 10 years is the recommended modality; however, if unavailable, flexible sigmoidoscopy every 5 years coupled with annual G-FOBT or FIT should be considered. FIT is preferred over G-FOBT | - |
- Citation: Wu YP, Chen M, Wang L. Current colorectal cancer screening in developing countries: Identifying optimal approaches. World J Gastroenterol 2026; 32(26): 118151
- URL: https://www.wjgnet.com/1007-9327/full/v32/i26/118151.htm
- DOI: https://dx.doi.org/10.3748/wjg.118151